Compare AIN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | ANAB |
|---|---|---|
| Founded | 1895 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.3B |
| IPO Year | 1994 | 2015 |
| Metric | AIN | ANAB |
|---|---|---|
| Price | $54.04 | $64.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | $60.25 | ★ $70.60 |
| AVG Volume (30 Days) | 291.7K | ★ 441.3K |
| Earning Date | 06-01-2026 | 05-25-2026 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,054,132,000.00 | $234,603,000.00 |
| Revenue This Year | $2.89 | N/A |
| Revenue Next Year | N/A | $43.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 7.29 | ★ 157.01 |
| 52 Week Low | $41.15 | $15.32 |
| 52 Week High | $75.16 | $66.66 |
| Indicator | AIN | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 66.56 |
| Support Level | $52.23 | $43.67 |
| Resistance Level | $60.43 | N/A |
| Average True Range (ATR) | 2.02 | 3.73 |
| MACD | -0.61 | 0.66 |
| Stochastic Oscillator | 18.88 | 85.12 |
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).